AstraZeneca: promising trial in endometrial cancer
Additional secondary endpoints showed consistent results for pMMR patients treated with Lynparza and Imfinzi, demonstrating a 32% reduction in the risk of second progression or death (PFS2) for the combination versus the control arm.
Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca, commented: 'DUO-E results have shown that the addition of Imfinzi to chemotherapy offers improved outcomes for patients with advanced endometrial cancer'.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction